Product image of Lipofib (Fenofibrate Micronised) supplied by GNH India

Lipofib

Active Ingredient:
Fenofibrate Micronised
Origin:
EU

Lipofib (Fenofibrate Micronised)

Fenofibrate, the active ingredient in Lipofib, is a fibrate presented as a micronised oral tablet for oral use. It is employed to lower elevated triglyceride levels and improve lipid profiles in adults with dyslipidaemia, including mixed dyslipidaemia and primary hypercholesterolemia.

GNH India supplies Lipofib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for patients in need. The company adheres to stringent regulatory standards and ensures consistent product availability across global markets.

Manufacturer / TM Owner

Terapia S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Fenofibrate acts on lipid metabolism disorders, helping to normalize triglyceride and cholesterol levels.
  • Hypertriglyceridemia: reduces serum triglycerides and lowers risk of pancreatitis.
  • Mixed dyslipidemia: lowers triglycerides, modestly raises HDL and reduces LDL.
  • Primary hypercholesterolemia: improves overall lipid profile when used with statins.

How It Works

  • Fenofibrate activates peroxisome proliferator‑activated receptor‑alpha (PPARα), a nuclear transcription factor that regulates genes involved in fatty‑acid oxidation, lipoprotein metabolism and inflammation. Activation increases lipolysis of triglyceride‑rich particles, enhances clearance of very‑low‑density lipoproteins, and raises high‑density lipoprotein synthesis, resulting in lowered plasma triglycerides and modest reductions in LDL cholesterol.

Side Effects

Fenofibrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
  • Headache: mild to moderate intensity.
  • Elevated liver enzymes: transient increase in ALT/AST.
  • Muscle aches: mild myalgia without weakness.

Serious or Rare Side Effects

  • Severe liver injury: jaundice or hepatitis.
  • Rhabdomyolysis: muscle breakdown with dark urine and possible renal impairment.
  • Allergic reactions: rash, pruritus or angioedema.

Precautions & Warnings

Before prescribing Lipofib, clinicians should consider several safety aspects.

  • Renal function: assess before initiating therapy in patients with impaired kidney function.
  • Hepatic function: monitor liver enzymes regularly during treatment.
  • Drug interactions: avoid concomitant use with potent CYP2C8 inhibitors.
  • Pregnancy and lactation: use only if potential benefit outweighs risk.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Fenofibrate can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

  • Cyclosporine: may increase fenofibrate plasma levels, raising risk of toxicity.
  • Gemfibrozil: combined fibrate therapy can markedly increase risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely)

  • Statins (especially simvastatin): increased risk of muscle toxicity; monitor CK levels.
  • Warfarin: fenofibrate may enhance anticoagulant effect; monitor INR.
  • Antidiabetic agents: may affect glycemic control; monitor blood glucose.

Frequently Asked Questions

Lipofib contains fenofibrate and is prescribed to lower high triglyceride levels and improve overall lipid profiles in adults with hypertriglyceridemia, mixed dyslipidemia, or primary hypercholesterolemia, often as part of a broader lipid‑management plan.

Fenofibrate activates the nuclear receptor PPARα, which regulates genes that increase fatty‑acid oxidation and the clearance of triglyceride‑rich lipoproteins, while also raising HDL cholesterol and modestly lowering LDL cholesterol.

The specific dose of Lipofib is determined by the prescribing clinician based on the patient’s lipid profile, renal and hepatic function, and any concomitant medications. Dosage adjustments are made according to individual therapeutic response.

Safety data for fenofibrate during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Lipofib, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other fibrates such as gemfibrozil, fenofibrate generally offers a broader effect on both triglycerides and HDL cholesterol, with a lower incidence of certain drug‑interaction‑related muscle toxicities. However, individual response varies, and clinicians choose therapy based on patient‑specific factors.

Store Lipofib at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and light, and keep it out of reach of children.

Lipofib is taken orally, usually with a meal to enhance absorption and reduce gastrointestinal upset. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events include severe liver injury, rhabdomyolysis (muscle breakdown that can lead to kidney failure), and allergic reactions such as rash or angioedema. Patients should report unexplained muscle pain, dark urine, jaundice, or signs of an allergic response immediately.

Lipofib is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, and it should be avoided in individuals with severe liver disease, active gallbladder disease, or uncontrolled renal impairment unless closely monitored.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fenofibrate Micronised

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT